帕博利珠单抗或CDK4/6抑制剂治疗患者胸肌前两阶段乳房重建的手术结局
帕博利珠单抗组扩张期血清肿率、假体置换后主要并发症和再手术率显著更高;CDK4/6抑制剂组未增加感染风险,轻微感染率反而更低。
要点
- 帕博利珠单抗组扩张期血清肿率44.4% vs 27%(p=0.05)。
- 帕博利珠单抗组假体置换后主要并发症26.3% vs 8%(p=0.02)。
- CDK4/6抑制剂组轻微感染率0.0% vs 12.4%(p=0.04),未增加感染风险。
核心结论
- 帕博利珠单抗与扩张期血清肿、假体置换后主要并发症及再手术率升高相关,需进一步研究。
- CDK4/6抑制剂与组织扩张器置入后感染风险增加无关。
研究设计与样本
- 共472例患者,其中27例接受帕博利珠单抗,30例接受CDK4/6抑制剂。
- 排除自体、延迟或直接置入假体重建及假体置换后化疗者。
- 主要并发症定义为需再入院或再手术。
- 统计分析采用Fisher精确检验和Wilcoxon秩和检验。
主要发现
- 帕博利珠单抗组扩张期血清肿率44.4% vs 27%(p=0.05)。
- 帕博利珠单抗组假体置换后主要并发症率26.3% vs 8%(p=0.02)。
- 帕博利珠单抗组再手术率19.1% vs 3.7%(p=0.01)。
- CDK4/6抑制剂组轻微感染率0.0% vs 12.4%(p=0.04),其他结局无显著差异。
关键数值与推荐
- 主要并发症定义为需再入院或再手术。
- 帕博利珠单抗组扩张期血清肿率44.4% vs 27%(p=0.05)。
- 帕博利珠单抗组假体置换后主要并发症率26.3% vs 8%(p=0.02)。
- 帕博利珠单抗组再手术率19.1% vs 3.7%(p=0.01)。
- CDK4/6抑制剂组轻微感染率0.0% vs 12.4%(p=0.04)。
临床怎么用
- 对接受帕博利珠单抗的患者行胸肌前两阶段乳房重建时,应警惕血清肿、主要并发症和再手术风险。
- 使用CDK4/6抑制剂的患者行组织扩张器置入时,感染风险未见增加。
局限性
- 单中心回顾性研究,样本量有限,帕博利珠单抗组27例、CDK4/6抑制剂组30例。
- 随访时间≥3个月,可能不足以捕捉远期并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Targeted therapies, including pembrolizumab and CDK4/6 inhibitors, have expanded treatment options for breast cancer subtypes such as triple-negative (TNBC) and hormone receptor-positive/HER2-negative cancers. However, their impact on surgical outcomes in two-stage prepectoral breast reconstruction remains unclear. This study evaluates surgical outcomes in patients receiving pembrolizumab or CDK4/6 inhibitors. METHODS: A retrospective review was conducted of all patients at a single institution who underwent immediate two-stage prepectoral reconstruction at a single center between January 2018 and October 2024 with ≥3 months of follow-up. Exclusion criteria included autologous, delayed, or direct-to-implant reconstructions, and chemotherapy after implant exchange. Variables analyzed included cancer characteristics, treatments, and postoperative complications. Major complications were defined as those requiring readmission or reoperation. Statistical analyses were performed using Fisher's Exact and Wilcoxon Rank Sum tests. RESULTS: Of 472 patients, 27 received pembrolizumab and 30 received CDK4/6 inhibitors. Pembrolizumab had significantly higher seroma rates during expansion (44.4% vs. 27%, p=0.05). After implant exchange, major complications (26.3% vs. 8%, p=0.02) and reoperation rates (19.1% vs. 3.7%, p=0.01) were significantly higher. Patients receiving CDK4/6 inhibitors did not experience an increased risk of infection; in fact, the observed rate of minor infections was lower (0.0% vs. 12.4%, p=0.04), although no significant differences were seen in other outcomes. CONCLUSION: Pembrolizumab is a promising therapy for TNBC, but its association with increased seromas, major complications, and reoperations warrants further investigation. Use of CDK4/6 inhibitors was not associated with an increased risk of infection following tissue expander placement.
引用
- Ibrahim Y, Alnaseri T, Gupta N, et al. Surgical Outcomes of Prepectoral Two-Stage Breast Reconstruction in Patients Treated with Pembrolizumab or CDK4/6 Inhibitors. Plast Reconstr Surg. 2026. PMID: 41825078. doi:10.1097/PRS.0000000000013032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。